AbbVie signed an option‑to‑license agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a trispecific T‑cell engager targeting DLL3. AbbVie will pay $100 million upfront for global development and commercialization rights outside Greater China; Zejing retains development and commercialization in Greater China and could receive additional near‑term option payments totaling $60 million. The arrangement could swell above $1.07 billion with development and commercial milestones. ZG006 is in Phase I/II for DLL3‑expressing tumors, and the deal follows regulatory momentum for DLL3‑targeted therapies in small‑cell lung cancer.